Caligan Partners LP Purchases New Shares in ABIVAX Société Anonyme (NASDAQ:ABVX)

Caligan Partners LP acquired a new stake in ABIVAX Société Anonyme (NASDAQ:ABVX) during the fourth quarter, HoldingsChannel reports. The firm acquired 752,167 shares of the company’s stock, valued at approximately $5,506,000. ABIVAX Société Anonyme accounts for 1.5% of Caligan Partners LP’s holdings, making the stock its 12th largest position.

Other institutional investors and hedge funds have also made changes to their positions in the company. abrdn plc increased its holdings in shares of ABIVAX Société Anonyme by 34.1% in the fourth quarter. abrdn plc now owns 424,181 shares of the company’s stock valued at $3,105,000 after purchasing an additional 107,750 shares during the period. JPMorgan Chase & Co. acquired a new stake in shares of ABIVAX Société Anonyme in the 4th quarter worth $5,336,000. GAMMA Investing LLC acquired a new position in ABIVAX Société Anonyme during the 4th quarter worth approximately $29,000. Guggenheim Capital LLC purchased a new position in ABIVAX Société Anonyme in the fourth quarter worth $92,000. Finally, Franklin Resources Inc. boosted its holdings in ABIVAX Société Anonyme by 10.7% during the fourth quarter. Franklin Resources Inc. now owns 1,466,062 shares of the company’s stock worth $10,732,000 after buying an additional 141,710 shares in the last quarter. 47.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ABVX has been the subject of several research analyst reports. Morgan Stanley reaffirmed an “equal weight” rating and issued a $12.00 price objective on shares of ABIVAX Société Anonyme in a research note on Thursday, March 20th. JMP Securities restated a “market outperform” rating and issued a $33.00 price target on shares of ABIVAX Société Anonyme in a research report on Wednesday. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $34.00.

ABIVAX Société Anonyme Price Performance

ABIVAX Société Anonyme stock opened at $7.12 on Thursday. The stock has a fifty day moving average of $6.61 and a two-hundred day moving average of $7.58. ABIVAX Société Anonyme has a fifty-two week low of $4.77 and a fifty-two week high of $15.43.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.